Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07447817 · ClinicalTrials.gov registry record · Phase 2
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
A Phase 2 study, sponsored by John Mascarenhas.
- Not yet
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT07447817: Clinical Trial Phase 2 study, sponsored by John Mascarenhas.
NCT07447817 is a Phase 2 study that has not yet begun recruiting, run by John Mascarenhas. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07447817, a Phase 2 study, has not yet begun recruiting, sponsored by John Mascarenhas.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Primary Outcome
Evaluate clinical efficacy of pacritinib and selinexor in myelofibrosis patients who are JAK inhibitor-naïve and have anemia and thrombocytopenia by assessing spleen volume reduction (SVR) of 35% or greater compared to baseline as measured by imaging (MRI/CT)
Interventions
- DRUG Selinexor
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-05-04 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 2 |
What is known before NCT07447817 opens enrollment
NCT07447817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Selinexor is the first listed.
NCT07447817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07447817 about?
NCT07447817 is a clinical study titled "Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias". This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
What is the current status of trial NCT07447817?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2026-05-04. Estimated completion is 2030-05-24.
What interventions are being tested in trial NCT07447817?
The interventions under investigation include: Selinexor (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT07447817?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07447817's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI